Search results
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine - Moderna (NASDAQ:MRNA)
Benzinga· 6 days agoManufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Moderna, Inc. (NASDAQ:MRNA)